Posaconazole therapy for severe abdominal candidiasis: A case report

Revista Iberoamericana de Micologia

Volumn 21, Issue 2, 2004, Pages 79-81

  Tobón, Angela M ^a   Correa, Ana L ^b   Arango, Myrtha ^a,c   De Bedout, Catalina ^a   Restrepo, Angela ^a  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Candida albicans; Candida tropicalls; Candidiasis; Fluconazole; Human; Posaconazole; SCH56592

Indexed keywords

CILASTATIN PLUS IMIPENEM; FLUCONAZOLE; POSACONAZOLE;

ABDOMINAL INFECTION; AGED; ARTICLE; ASCITES FLUID; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE COURSE; FEMALE; FUNGUS ISOLATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL DISCHARGE; HUMAN; LIVER CYST; MALLORY WEISS SYNDROME; PATIENT MONITORING; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; VOMITING;

ABDOMEN; AGED; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CYSTS; FEMALE; HUMANS; LIVER DISEASES; POSTOPERATIVE COMPLICATIONS; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; FUNGI; NEGIBACTERIA; POMACANTHUS MACULOSUS;

EID: 10844232891     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
2. Barchiesi F, Arzeni D, Fothergill AW, Di Francesco LF, Caselli F, Rinaldi MG, Scalise G. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44: 226-229.
3. Bille J, Glauser MP. Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 924-928.
4. Muñoz R Pérez Fernández-Turégano C, Alcalá L, Rodríguez-Créixems M, Peláez T, Bouza A. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis 2002; 44: 163-167.
5. de Bedout C, Ayabaca J, Vega R, Méndez M, Santiago AR, Pabón ML, Tabares A, Arango M, Restrepo A, Newell V. Evaluación de la susceptibilidad de especies de Candida al fluconazol por el método de difusión de disco. Biomédica 2003; 23: 31-37.
6. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm 2002; 59: 33-41.
7. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260.
8. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50: 119-123.
9. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751.
10. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862-2864.
11. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42: 3242-3244.
12. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; 35: 19-25.
13. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
14. St-Germain G, Laverdiere M, Pelletier R, Boutgault AM, Libman M, Lemieux C, Noel G. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) mufticenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949-953.
15. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.